547 related articles for article (PubMed ID: 29165790)
1. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
2. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
4. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
5. Oncologist use and perception of large panel next-generation tumor sequencing.
Schram AM; Reales D; Galle J; Cambria R; Durany R; Feldman D; Sherman E; Rosenberg J; D'Andrea G; Baxi S; Janjigian Y; Tap W; Dickler M; Baselga J; Taylor BS; Chakravarty D; Gao J; Schultz N; Solit DB; Berger MF; Hyman DM
Ann Oncol; 2017 Sep; 28(9):2298-2304. PubMed ID: 28911072
[TBL] [Abstract][Full Text] [Related]
6. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
7. Clinical Use of Precision Oncology Decision Support.
Johnson A; Khotskaya YB; Brusco L; Zeng J; Holla V; Bailey AM; Litzenburger BC; Sanchez N; Shufean MA; Piha-Paul S; Subbiah V; Hong D; Routbort M; Broaddus R; Mills Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F
JCO Precis Oncol; 2017; 2017():. PubMed ID: 30320296
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
9. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.
Johnson LM; Valdez JM; Quinn EA; Sykes AD; McGee RB; Nuccio R; Hines-Dowell SJ; Baker JN; Kesserwan C; Nichols KE; Mandrell BN
Cancer; 2017 Jun; 123(12):2352-2359. PubMed ID: 28192596
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
11. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making.
Dumbrava EI; Meric-Bernstam F
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29212833
[TBL] [Abstract][Full Text] [Related]
12. Knowledge base toward understanding actionable alterations and realizing precision oncology.
Takeuchi S; Okuda S
Int J Clin Oncol; 2019 Feb; 24(2):123-130. PubMed ID: 30542800
[TBL] [Abstract][Full Text] [Related]
13. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
14. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
[TBL] [Abstract][Full Text] [Related]
15. Actionability classification of variants of unknown significance correlates with functional effect.
Johnson A; Ng PK; Kahle M; Castillo J; Amador B; Wang Y; Zeng J; Holla V; Vu T; Su F; Kim SH; Conway T; Jiang X; Chen K; Shaw KRM; Yap TA; Rodon J; Mills GB; Meric-Bernstam F
NPJ Precis Oncol; 2023 Jul; 7(1):67. PubMed ID: 37454202
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
17. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
18. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
19. Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.
Araya A; Zeng J; Johnson A; Shufean MA; Rodon J; Meric-Bernstam F; Bernstam EV
Int J Med Inform; 2020 Nov; 143():104261. PubMed ID: 32889387
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.
Bieg-Bourne CC; Millis SZ; Piccioni DE; Fanta PT; Goldberg ME; Chmielecki J; Parker BA; Kurzrock R
Cancer Res; 2017 Nov; 77(22):6313-6320. PubMed ID: 28939679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
